The Shingles Vaccine May Be Our Best Alzheimer's Drug — And We Already Have It

The most promising lead in Alzheimer's research right now might already be sitting in your pharmacist's fridge. After reviewing 80 existing drugs for their potential to be repurposed against the disease, an international panel of experts has identified three candidates that stand out from the rest: Zostavax, the shingles vaccine; sildenafil, better known as Viagra; and riluzole, a drug currently used to slow the progression of ALS. The finding reframes a question the field has been asking for decades. Instead of asking what new molecule might defeat Alzheimer's, researchers are now asking what tools we already have.

The study, which drew on a broad review of existing pharmacological literature, is significant not just for what it found but for what it implies about the economics and incentives of drug development. Alzheimer's research has historically been dominated by the amyloid hypothesis, the idea that sticky plaques of amyloid protein in the brain are the primary driver of the disease. Billions of dollars and decades of clinical trials have been poured into drugs designed to clear those plaques, with largely disappointing results. The pivot toward drug repurposing represents something of an institutional admission that the field may have been looking in the wrong direction, or at least through too narrow a lens.

Zostavax's emergence as the front-runner is perhaps the most striking finding, and it carries the most immediate public health weight. The vaccine, designed to prevent shingles by suppressing the varicella-zoster virus, has shown in large observational studies a meaningful reduction in dementia risk among people who received it. The leading hypothesis is that the herpes family of viruses, which includes varicella-zoster, may play a role in triggering or accelerating neuroinflammation, one of the key mechanisms now understood to drive Alzheimer's progression. If a virus that lies dormant in the nervous system is periodically reactivating and quietly inflaming brain tissue over years, then suppressing it with a vaccine is not a peripheral intervention. It is a direct strike at a root cause.

Sildenafil's inclusion is less intuitive but not without logic. Originally developed to treat pulmonary arterial hypertension and later repurposed for erectile dysfunction, the drug works by inhibiting an enzyme called PDE5, which increases blood flow. The brain is extraordinarily dependent on healthy vascular function, and cerebrovascular disease is now understood to be deeply intertwined with Alzheimer's pathology rather than a separate condition running alongside it. Improved cerebral blood flow, reduced vascular inflammation, and possible direct neuroprotective effects have all been proposed as mechanisms. A large insurance claims database study published in Nature Aging in 2021 found that sildenafil users had a significantly lower incidence of Alzheimer's diagnosis, though researchers were careful to note that correlation is not causation and that a clinical trial would be needed to confirm the effect.

Riluzole, the ALS drug, rounds out the trio. It modulates glutamate signalling in the brain, reducing excitotoxicity, a process in which neurons are essentially overstimulated to death. Glutamate dysregulation has been observed in Alzheimer's patients, and riluzole has shown protective effects in animal models of the disease. Its existing safety profile, already established through its use in ALS patients, makes it a relatively low-risk candidate to advance into trials.

The systemic consequence that deserves the most attention here is not about any single drug. It is about what happens to the pharmaceutical pipeline if repurposed drugs prove effective. Drug repurposing is, by its nature, a threat to the traditional blockbuster model of pharmaceutical development. Zostavax, sildenafil, and riluzole are all off-patent or approaching the end of their commercial peak. There is limited financial incentive for a major pharmaceutical company to fund the large, expensive clinical trials needed to formally establish a new indication for a drug it cannot exclusively profit from. This is a structural problem that public funding bodies and academic consortia will need to solve if repurposing is to fulfil its promise.

The National Institutes of Health and equivalent bodies in Europe have begun to recognise this gap, but the funding has not yet matched the scale of the opportunity. If a shingles vaccine can meaningfully reduce dementia risk across a population, the public health return on investment would be extraordinary, running into hundreds of billions of dollars in reduced care costs globally. The tragedy would be if that intervention stalled not because the science failed, but because no single actor had enough financial incentive to carry it across the finish line.

What this moment really signals is that Alzheimer's may be less a single disease waiting for a single cure and more a convergence of vascular, viral, and neurochemical failures that different drugs address from different angles. The next decade of research may look less like a race to find the one answer and more like the careful assembly of a combination therapy, built from medicines we already trust.